KYV-101 is named as a drug or biological intervention in 3 clinical trials in our USA and UK trial registers, 2 of which are recruiting. The lead sponsor is Kyverna Therapeutics. Registered phases: Phase 2/3, Phase 2 and Observational. Conditions studied include Myasthenia Gravis; Generalized Myasthenia Gravis; Multiple Sclerosis, Primary Progressive.
| NCT ID | Study | Phase | Status |
|---|---|---|---|
| NCT06193889 | KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis Myasthenia Gravis, Generalized Myasthenia Gravis |
Phase 2/3 | Recruiting |
| NCT07403188 | A Long-Term Follow-Up Study for Participants Previously Treated With KYV-101 (ClinicalTrials.gov ↗) Refractory Lupus Nephritis, Myasthaenia Gravis, Stiff Person Syndrome |
Observational | Recruiting |
| NCT06384976 | KYSA-7: A Study of Anti-CD19 CAR T-Cell Therapy, in Subjects With Refractory Primary and Secondary Progressive Multiple Sclerosis (ClinicalTrials.gov ↗) Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive, Multiple Sclerosis |
Phase 2 | Active, closed |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Myasthenia Gravis | 1 |
| Generalized Myasthenia Gravis | 1 |
| Multiple Sclerosis, Primary Progressive | 1 |
| Multiple Sclerosis, Secondary Progressive | 1 |
| Multiple Sclerosis | 1 |
| MS | 1 |
| Refractory Lupus Nephritis | 1 |
| Myasthaenia Gravis | 1 |
| Stiff Person Syndrome | 1 |
| Rheumatoid Arthritis (RA) | 1 |
| Lead sponsor | Trials |
|---|---|
| Kyverna Therapeutics | 3 |
| Register | KYV-101 trials |
|---|---|
| Clinical trials in USA | 3 |
| Clinical trials in UK | 1 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how KYV-101 works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists KYV-101 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.